News

Reviewing the FDA Advisory Committee Decision on MDMA

What are the connections between environmental factors and the development of mental disorders?

John J. Miller, MD

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

Mehdi Farokhnia, MD, MPH

FDA Panel Votes Against MDMA-Assisted Therapy

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

Leah Kuntz

Terms of the Social: Updating the Lexicon of Social Psychiatry

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA

Presenting Our June Theme: Stress and Anxiety

Society starts with two—one is a fiction.

Write to us now to be part of our series focused on stress and anxiety this month.

The Role of Psychedelics in Psychiatry: A Conversation With Rachel Dalthorp, MD, MHSA

Write to us now to be part of our series focused on stress and anxiety this month.

Leah Kuntz;Rachel Dalthorp, MD, MHSA

Why Generosity is a Psychoexemplary

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

H. Steven Moffic, MD

What we need more of: generosity.

A Poet's Lament

Frank A. Clark, MD

Clinicians Excited About FDA Committee Meeting: Patients Deserve More Options

A psychiatrist reflects and laments on the state of the country.

Carmen Kosicek, MSN, PMHNP-BC

Why Clinicians Should Be Excited About Austedo XR

Carmen Kosicek, MSN, PMHNP-BC, and team share their excitement over potential new options pending the FDA's Advisory Committee meeting.

Leah Kuntz;Rakesh Jain, MD, MPH

First Participant Dosed in Study of BPL-003 Neurophysiological Effects

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Leah Kuntz

A Critical Step Forward: A Clinician’s Thoughts on MDMA-Assisted Therapy

Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.

Leah Kuntz;Kelley O’Donnell, MD, PhD

A Skeptical Look at MDMA From a PTSD Expert

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Leah Kuntz;David N. Osser, MD

MDMA-Assisted Therapy for PTSD: A Conversation With Amy Emerson, CEO of Lykos Therapeutics

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

Leah Kuntz;Amy Emerson

The Cutting Edge of Medicine: An Interview With Alejandro Alva, MD

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

Leah Kuntz;Alejandro Alva, MD

The Psychoexemplary of Compassionating as Mexico Elects Its First Woman and Jewish President

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

H. Steven Moffic, MD

Psychedelics Recommendations Poll

The importance of compassion.

Psychiatric Times Editors

June 2nd 2024

Answer a quick question on psychedelics!

Psychedelics Utilization Poll

Psychiatric Times Editors

June 1st 2024

Answer a quick question about psychedelics!

Critical Care Psychiatry: The Value of Psychiatrists in the ICU

Joseph D. Dragonetti, MD;Melissa P. Bui, MD;Marie E. Rueve, MD, MHA, FAPA;James A. Bourgeois, OD, MD

Psychedelics Beyond Clinical Settings Poll

In this CME article, learn more about common clinical conditions, consultation questions, and challenges in the field of critical care psychiatry.

Psychiatric Times Editors

Poster Explores Safety, Efficacy of Seltorexant for MDD, Insomnia

Answer a quick question on psychedelics!

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

Post Hoc Analysis Explores Risk-Benefit Profile of KarXT

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

Anthem for Doomed Youth

Richard M. Berlin, MD

Efficacy of Esketamine Nasal Spray for TRD in Real-World Clinical Settings

"Not in the hands of boys, but in their eyes, Shall shine the holy glimmers of goodbyes."

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

The Verdict Is In: Statesmanship as a Leadership Psychoexemplary

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

H. Steven Moffic, MD

Evaluating the Efficacy of Lumateperone for MDD and Bipolar Depression With Mixed Features

The need for effective leadership is apparent.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.